» Articles » PMID: 24508063

Honokiol Inhibits Epithelial-mesenchymal Transition in Breast Cancer Cells by Targeting Signal Transducer and Activator of Transcription 3/Zeb1/E-cadherin Axis

Overview
Journal Mol Oncol
Date 2014 Feb 11
PMID 24508063
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-mesenchymal transition (EMT), a critical step in the acquisition of metastatic state, is an attractive target for therapeutic interventions directed against tumor metastasis. Honokiol (HNK) is a natural phenolic compound isolated from an extract of seed cones from Magnolia grandiflora. Recent studies from our lab show that HNK impedes breast carcinogenesis. Here, we provide molecular evidence that HNK inhibits EMT in breast cancer cells resulting in significant downregulation of mesenchymal marker proteins and concurrent upregulation of epithelial markers. Experimental EMT induced by exposure to TGFβ and TNFα in spontaneously immortalized nontumorigenic human mammary epithelial cells is also completely reversed by HNK as evidenced by morphological as well as molecular changes. Investigating the downstream mediator(s) that may direct EMT inhibition by HNK, we found functional interactions between HNK, Stat3, and EMT-signaling components. In vitro and in vivo analyses show that HNK inhibits Stat3 activation in breast cancer cells and tumors. Constitutive activation of Stat3 abrogates HNK-mediated activation of epithelial markers whereas inhibition of Stat3 using small molecule inhibitor, Stattic, potentiates HNK-mediated inhibition of EMT markers, invasion and migration of breast cancer cells. Mechanistically, HNK inhibits recruitment of Stat3 on mesenchymal transcription factor Zeb1 promoter resulting in decreased Zeb1 expression and nuclear translocation. We also discover that HNK increases E-cadherin expression via Stat3-mediated release of Zeb1 from E-cadherin promoter. Collectively, this study reports that HNK effectively inhibits EMT in breast cancer cells and provide evidence for a previously unrecognized cross-talk between HNK and Stat3/Zeb1/E-cadherin axis.

Citing Articles

Role of STAT3 in cancer cell epithelial‑mesenchymal transition (Review).

Zhang G, Hou S, Li S, Wang Y, Cui W Int J Oncol. 2024; 64(5).

PMID: 38488027 PMC: 11000535. DOI: 10.3892/ijo.2024.5636.


Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma.

Liu D, Wang L, Li H, Li D, Zhou J, Wang J Molecules. 2024; 29(3).

PMID: 38338418 PMC: 10856273. DOI: 10.3390/molecules29030675.


Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals.

Fakhri S, Moradi S, Abbaszadeh F, Faraji F, Amirian R, Sinha D Cancer Metastasis Rev. 2024; 43(1):261-292.

PMID: 38169011 DOI: 10.1007/s10555-023-10161-8.


Upregulation of tumor suppressor PIAS3 by Honokiol promotes tumor cell apoptosis via selective inhibition of STAT3 tyrosine 705 phosphorylation.

Fei Y, Zhang X, Wang X, Sun Y, He J, Liu X J Nat Med. 2023; 78(2):285-295.

PMID: 38082192 DOI: 10.1007/s11418-023-01757-z.


Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin.

Mikhaevich E, Sorokin D, Scherbakov A Res Pharm Sci. 2023; 18(5):580-591.

PMID: 37842518 PMC: 10568957. DOI: 10.4103/1735-5362.383712.


References
1.
Radisky D, LaBarge M . Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell. 2008; 2(6):511-2. DOI: 10.1016/j.stem.2008.05.007. View

2.
Lin Y, Chen H, Ko C, Chan M . Differential inhibitory effects of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures. Neuropharmacology. 2005; 49(4):542-50. DOI: 10.1016/j.neuropharm.2005.04.009. View

3.
Sehrawat A, Singh S . Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev Res (Phila). 2011; 4(7):1107-17. PMC: 3131421. DOI: 10.1158/1940-6207.CAPR-10-0306. View

4.
Fried L, Arbiser J . Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal. 2009; 11(5):1139-48. PMC: 2842137. DOI: 10.1089/ars.2009.2440. View

5.
Nagase H, Ikeda K, Sakai Y . Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med. 2001; 67(8):705-8. DOI: 10.1055/s-2001-18345. View